Mirvetuximab Soravtansine is named as a drug or biological intervention in 8 clinical trials in our USA, UK, Ireland, China and India trial registers, 4 of which are recruiting. Lead sponsors include AbbVie (6), AstraZeneca (1) and Fudan University (1). Registered phases: Phase 2 and Phase 3. Conditions studied include Fallopian Tube Cancer; Primary Peritoneal Cancer; Epithelial Ovarian Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Fallopian Tube Cancer | 3 |
| Primary Peritoneal Cancer | 3 |
| Epithelial Ovarian Cancer | 2 |
| Ovarian Cancer | 2 |
| Recurrent Ovarian Cancer | 1 |
| Folate Receptor-Alpha Positive | 1 |
| Peritoneal Cancer | 1 |
| Advanced High-Grade Epithelial Ovarian Cancer | 1 |
| Fallopian Tube Cancers | 1 |
| High Grade Ovarian Cancer | 1 |
| Neoadjuvant | 1 |
| Advanced or Metastatic Pancreatic Adenocarcinoma | 1 |
| Advanced or Metastatic Breast Cancer (BC) | 1 |
| Lead sponsor | Trials |
|---|---|
| AbbVie | 6 |
| AstraZeneca | 1 |
| Fudan University | 1 |
| Register | Mirvetuximab Soravtansine trials |
|---|---|
| Clinical trials in USA | 7 |
| Clinical trials in UK | 4 |
| Clinical trials in Ireland | 3 |
| Clinical trials in China | 3 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Mirvetuximab Soravtansine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mirvetuximab Soravtansine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.